

NOTICE: This is a translation of a notice in Japanese issued on June 23, 2017 and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

Securities code: 4536

June 23, 2017

**RESOLUTION NOTICE OF  
THE 105<sup>TH</sup> ANNUAL GENERAL MEETING OF SHAREHOLDERS OF  
SANTEN PHARMACEUTICAL CO., LTD.**

Dear Shareholder:

We hereby inform you of the reports and the resolutions that were made, as set forth below, in the 105<sup>th</sup> Annual General Meeting of Shareholders of the Company that was held today.

**Reports:**

1. Reports on the Business Report, Consolidated Financial Statements and Financial Statements for the 105<sup>th</sup> Business Term (April 1, 2016 to March 31, 2017)
2. Reports on the Audit Reports by the Accounting Auditors and the Board of Corporate Auditors on the Consolidated Financial Statements for the 105<sup>th</sup> Business Term (April 1, 2016 to March 31, 2017)

As regards the items set forth above, the contents thereof were reported.

**Resolved Items:**

**Proposal No. 1: Appropriation of Surplus**

As regards this item, the term-end dividends of profits were resolved to be JPY 13 per share as per the original proposal. Consequently, the total dividends for the annual business term, including the interim dividends previously distributed are JPY 26 per share.

**Proposal No. 2: Appointment of Seven (7) Directors**

As regards this item, Akira Kurokawa, Takeshi Ito, Akihiro Tsujimura, Shigeo Taniuchi, Takayuki Katayama, Kanoko Oishi and Yutaro Shintaku were appointed as per the original proposal; each of them assumed their respective offices.

Takayuki Katayama, Kanoko Oishi and Yutaro Shintaku are Outside Directors.

Yours very truly,

Akira Kurokawa  
Representative Director  
President & CEO  
SANTEN PHARMACEUTICAL CO., LTD.  
9-19, Shimoshinjo 3-chome, Higashiyodogawa-ku, Osaka, Japan  
[Corporate Headquarters: 4-20, Ofuka-cho, Kita-ku, Osaka, Japan]

## ANNOUNCEMENT

At the Board of Directors meeting, which was held after the close of this Annual General Meeting of Shareholders, Akira Kurokawa was appointed as President and CEO. He assumed the said offices.

As a result thereof, the Directors and Corporate Auditors of the Company and Corporate Officers of the Company on and after July 1, 2017 shall be as follows:

### Directors and Corporate Auditors

Akira Kurokawa	President and CEO
Takeshi Ito	Director Executive Corporate Officer, Japan Business Head of Japan Sales & Marketing, Prescription Pharmaceuticals
Akihiro Tsujimura	Director Executive Corporate Officer, Asia and North America Businesses Head of Asia Division, President & CEO of Santen Inc.
Shigeo Taniuchi	Director Senior Corporate Officer, Head of Santen EMEA President of Santen Holdings EU B.V.
Takayuki Katayama *	Director
Kanoko Oishi *	Director
Yutaro Shintaku*	Director
Masashi Murata	Standing Corporate Auditor
Yutaka Mizuno**	Corporate Auditor
Koichi Matsuzawa **	Corporate Auditor
Seiichiro Adachi **	Corporate Auditor

\* The Outside Directors (indicated by an asterisk (\*) next to their names) are Independent Officers (as set forth in Article 436-2, Paragraph 1 of the Securities Listing Regulations of the Tokyo Stock Exchange, Inc.; hereinafter, the same classification shall apply.)

\*\*The Outside Corporate Auditors (indicated by two asterisks (\*\*)) next to their names) are Independent Officers.

**Corporate Officers (excluding Corporate Officers who are also Members of the Board)**

Masamichi Sato	Senior Corporate Officer Chief Compliance Officer (CCO) Head of CSR & Internal Control Division CEO of Santen Business Services Co., Ltd
Naveed Shams	Senior Corporate Officer Chief Scientific Officer (CSO) Head of Global Research & Development
Atsutoshi Ota	Senior Corporate Officer Head of Human Resources Development Division
Kazuo Koshiji	Senior Corporate Officer Chief Financial Officer (CFO) Head of Finance Division
Kenji Morishima	Corporate Officer Head of Pharmaceutical Technology Development
Akio Kimura	Corporate Officer Head of Global Product Supply
Noriaki Yamamoto	Corporate Officer Chief Information Officer (CIO) Head of Information Systems Division
Satoshi Suzuki	Corporate Officer Head of Corporate Development Division
Ye Liu	Corporate Officer General Manager Santen Pharmaceutical (China) Co., Ltd.
Takahiro Morita	Corporate Officer Head of Japan Prescription Pharmaceuticals Sales

End.